Over the past six years, the biopharmaceutical sector has evolved significantly in response to growing global demand for biological therapeutic research, development and manufacturing capabilities. This transformation has increased the importance of not only tangible assets and biological materials, but also process innovation, technical expertise, specialized knowledge services and data handling. While these advances have accelerated innovation and strengthened the sector’s responsiveness, they have also introduced new challenges in aligning industry operations with international non-proliferation frameworks.
In this context, the event will provide a platform for dialogue between governments and biotechnology industry stakeholders to demonstrate how collaborative engagement can ensure that non-proliferation safeguards remain both technically feasible and proportionate to genuine security concerns, while remaining responsive to the evolving needs of a dynamic, pandemic-prepared biopharmaceutical sector. Through this partnership, international norms can be strengthened while continuing to support innovation and sustainable sectoral growth under the BWC.